Assessment of mitotic activity in pituitary adenomas and carcinomas

Endocrine Pathology

Volumn 7, Issue 3, 1996, Pages 215-221

  Thapar, Kamal ^a   Yamada, Yukio ^b   Scheithauer, Bernd ^c   Kovacs, Kalman ^a   Yamada, Shozo ^d   Stefaneanu, Lucia ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TOKYO   (Japan)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d TORANOMON HOSPITAL   (Japan)

Author keywords

Invasiveness; Ki 67; Mitotic index; Pituitary adenomas; Pituitary carcinomas; Proliferation markers

Indexed keywords

EID: 0000228184     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02739924     Document Type: Article

References (14)

1. Clayton F, Hopkins C. Pathologic correlates of prognosis in lymph node positive breast carcinomas. Cancer 71:1780-1790, 1993.
2. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal carcinomas. Mitotic count is the best single indicator. Cancer 68:1309-1317, 1991.
3. van Diest P, Baak J. The morphometric prog3 nostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node positive breast cancer patients. Hum Pathol 22:326-330, 1991.
4. Wilson C. Role of surgery in the management of pituitary tumors. Neurosurg Clin N Am 1:139-159, 1990.
5. Wilson C. A decade of pituitary microsurgery: the Herbert Olivecrona lecture. J Neurosurg 61:814-833, 1984.
6. Selman WR, Laws ERJ, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64:402-407, 1984.
7. Scheithauer B, Kovacs K, Laws EJ, Randall R. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733-744, 1986.
8. Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas: results in 100 patients. Mayo Clin Proc 58:108-121, 1983.
9. Laws ER Jr, Scheithauer B, Carpenter S, Randall R, Abboud C. The pathogenesis of acromegaly: clinical and immunocytochemical analysis in 75 patients. J Neurosurg 63:35-38, 1984.
10. Laws E, Thapar K. Surgical management of pituitary tumors. Ballière's Clin Endocrinol Metab 9(2):391-406, 1995.
11. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99-107, 1996.
12. Taylor CR, Shan-Rong S, Chaiwun B, Young L, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 25:263-270, 1994.
13. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75:816-821, 1981.
14. Kramer A, Saeger W, Tallen G, Ludecke D. DNA measurement, proliferation markers, and other factors in pituitary adenomas. Endocr Pathol 5:198-211, 1994.